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Abstract
Françoise Barré-Sinoussi and Luc Montagnier, codiscoverers of HIV, the causative agent of AIDS,
have been awarded the 2008 Nobel Prize in Physiology or Medicine. They share this prize with
Harald zur Hausen who was responsible for establishing the link between human papilloma virus
infection and cervical carcinoma.
Editorial
Nobel prizes have often attracted controversy and contro-
versial figures. William Ramsay was awarded the Nobel
prize in Chemistry for the discovery of inert gases and sub-
sequently went on to claim chemical transmutation of ele-
ments. Individual, institutional and national pride are all
at stake when they are announced. One small Cambridge
college boasts unashamedly of having been the workplace
of no less than four Nobel Laureates including Perutz,
Kendrew and Klug. Their value is more than financial and
the method of their choosing somewhat mysterious and,
to some peoples' minds flawed. Arrhenius having won in
1903, reputedly then manipulated future choices in
favour of his friends and attempted (unsuccessfully) to
exclude some very significant scientific figures such as
Paul Ehrlich.
This year virology has been honoured and three scientists
chosen who worked with two very different viruses. Har-
ald zur Hausen, professor emeritus of the German Cancer
Research Center in Heidelberg (Germany) identified the
link between human papilloma virus (HPV) infection and
cervical cancer. It is timely that with the recent develop-
ment of a safe and effective vaccine he should be recog-
nised for first identification of this human pathogenic
virus. He made several particularly noteworthy findings in
papilloma virus research. The earliest was the recognition
that there are multiple HPV genotypes, particularly that
HPVs that cause non-genital warts are distinct from those
that cause genital warts. His most important finding was
the identification and molecular cloning of the HPV types
16 and 18 genomes, and that a majority of cervical cancers
contained DNA from these two HPV types. A third critical
finding was that the HPV DNA becomes integrated into
the host genome in cervical cancer cell lines and that the
viral E6 and E7 (onco)genes are preferentially retained
and expressed in the tumors. His work is even more note-
worthy because it was carried out in the 1980's when there
was considerable scepticism whether viruses in general,
and HPV in particular, caused any common cancers. Pro-
fessor zur Hausen has continued to run a highly produc-
tive laboratory since these seminal early findings. No
controversy thus far.
Retroviruses have generated more than their share of
Nobel prizes. Peyton Rous for retroviral oncogenesis
(1966), Temin and Baltimore for reverse transcriptase
(1975) and Varmus and Bishop again for oncogenes that
were originally described for retroviruses (1989). The
human immunodeficiency virus (HIV) as the largest pub-
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lic health problem in the world was destined to follow
sooner or later. The difference is that, unlike in papilloma
viruses, and whilst antiviral treatment has made astonish-
ing progress in 20 years, we are no nearer a cure and cer-
tainly years from a vaccine (should one ever be possible)
against HIV. The Nobel committee have chosen to honour
the scientists who most people agree were the first to actu-
ally isolate the virus at the Pasteur Institute in Paris
(France) in 1983: Françoise Barré-Sinoussi and Luc Mon-
tagnier. Following medical reports of a novel immunode-
ficiency syndrome in 1981, the search for a causative
agent was on. The French researchers isolated and cul-
tured cells from lymph nodes of patients with the lym-
phadenopathy characteristic of the early stage of acquired
immune deficiency. They detected activity of the retroviral
enzyme reverse transcriptase, a direct sign of retrovirus
replication. They also observed retroviral particles bud-
ding from the infected cells. Isolated virus infected and
killed lymphocytes from healthy donors and reacted with
antibodies from infected patients. By 1984, Barré-Sinoussi
and Montagnier had obtained several isolates of the novel
human retrovirus from sexually infected individuals, hae-
mophiliacs, mother to infant transmissions and trans-
fused patients.
Nobel prizes can be split between a maximum of three
individuals and sometimes a deserving fourth person has
been omitted on what appear to be relatively tough prag-
matic grounds. Had the Nobel committee decided this
year that the prize was for the discovery of HIV alone there
would have been only one possible third candidate. That
they didn't may be perceived in some quarters as a more
pointed statement. However the subjects into which the
prize is divided may be very diverse. Peyton Rous shared
his with Charles Huggins, honoured for his contribution
to hormonal treatment of cancer. Luc Montagnier (per-
haps with a winner's magnanimity) has said that the obvi-
ous third recipient should have been Robert Gallo. Others
will quote Gallo's identification of HTLV-1 with Bernie
Poiesz and the fact that many of the techniques used to
grow viruses like HIV were dependent on discoveries from
the Gallo lab as were some of the earliest blood tests for
the virus. Had the Nobel committee honoured only those
who contributed to the discovery of HIV rather than HPV
as well the picture may have been different. Instead they
chose to reward the two scientists most responsible for the
first isolation of the virus. These two indeed deserve our
congratulations. It would be churlish however not to
acknowledge that the work of others, notably the Gallo
lab – but also other scientists working at the time, and
since – made very significant contributions without which
it is likely that the unprecedented advances we have seen
in our understanding and successful therapy of HIV might
have been much slower in coming.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
Both authors contributed equally to the work.